Search

Your search keyword '"Mancheño, Nuria"' showing total 21 results
Start Over Author "Mancheño, Nuria"
21 results on '"Mancheño, Nuria"'

1. RET Fusion Testing in Patients With NSCLC: The RETING Study

Author

Conde, Esther, Hernandez, Susana, Rodriguez Carrillo, Jose Luis, Martinez, Rebeca, Alonso, Marta, Curto, Daniel, Jimenez, Beatriz, Caminoa, Alejandra, Benito, Amparo, Garrido, Pilar, Clave, Sergi, Arriola, Edurne, Esteban-Rodriguez, Isabel, De Castro, Javier, Sansano, Irene, Felip, Enriqueta, Rojo, Federico, Dómine, Manuel, Abdulkader, Ihab, Garcia-Gonzalez, Jorge, Teixido, Cristina, Reguart, Noemi, Compañ, Desamparados, Insa, Amelia, Mancheño, Nuria, Palanca, Sarai, Juan-Vidal, Oscar, Baixeras, Nuria, Nadal, Ernest, Cebollero, Maria, Calles, Antonio, Martin, Paloma, Salas, Clara, Provencio, Mariano, Aranda, Ignacio, Massuti, Bartomeu, Lopez-Vilaro, Laura, Majem, Margarita, Paz-Ares, Luis, and Lopez-Rios, Fernando

Published
2024
Full Text
View/download PDF

2. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

Author

Conde, Esther, Hernandez, Susana, Martinez, Rebeca, Angulo, Barbara, De Castro, Javier, Collazo-Lorduy, Ana, Jimenez, Beatriz, Muriel, Alfonso, Mate, Jose Luis, Moran, Teresa, Aranda, Ignacio, Massuti, Bartomeu, Rojo, Federico, Domine, Manuel, Sansano, Irene, Garcia, Felip, Felip, Enriqueta, Mancheño, Nuria, Juan, Oscar, Sanz, Julian, Gonzalez-Larriba, Jose Luis, Atienza-Cuevas, Lidia, Arriola-Arellano, Esperanza, Abdulkader, Ihab, Garcia-Gonzalez, Jorge, Camacho, Carmen, Rodriguez-Abreu, Delvys, Teixido, Cristina, Reguart, Noemi, Gonzalez-Piñeiro, Ana, Lazaro-Quintela, Martin, Lozano, Maria Dolores, Gurpide, Alfonso, Gomez-Roman, Javier, Lopez-Brea, Marta, Pijuan, Lara, Salido, Marta, Arriola, Edurne, Company, Amparo, Insa, Amelia, Esteban-Rodriguez, Isabel, Saiz, Monica, Azkona, Eider, Alvarez, Ramiro, Artal, Angel, Plaza, Maria Luz, Aguiar, David, Enguita, Ana Belen, Benito, Amparo, Paz-Ares, Luis, Garrido, Pilar, and Lopez-Rios, Fernando

Published
2019
Full Text
View/download PDF

5. Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for EGFR-Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients

Author

Simarro, Javier, primary, Pérez-Simó, Gema, additional, Mancheño, Nuria, additional, Ansotegui, Emilio, additional, Muñoz-Núñez, Carlos Francisco, additional, Gómez-Codina, José, additional, Juan, Óscar, additional, and Palanca, Sarai, additional

Published
2022
Full Text
View/download PDF

8. Correction: Pardo-Sánchez et al. Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation. Cancers 2021, 13, 2980

Author

Pardo-Sánchez, José Miguel, primary, Mancheño, Nuria, additional, Cerón, José, additional, Jordá, Carlos, additional, Ansotegui, Emilio, additional, Juan, Óscar, additional, Palanca, Sarai, additional, Cremades, Antonio, additional, Gandía, Carolina, additional, and Farràs, Rosa, additional

Published
2021
Full Text
View/download PDF

14. Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing.

Author

Conde, Esther, Rojo, Federico, Gómez, Javier, Enguita, Ana Belén, Abdulkader, Ihab, González, Ana, Lozano, Dolores, Mancheño, Nuria, Salas, Clara, Salido, Marta, Salido-Ruiz, Eduardo, and de Álava, Enrique

Subjects
ANAPLASTIC lymphoma kinase, CIRCULATING tumor DNA, NON-small-cell lung carcinoma, MOLECULAR diagnosis, SMALL cell lung cancer, LUNGS, CELL-free DNA
Published
2022
Full Text
View/download PDF

15. Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALKand ROS1testing

Author

Conde, Esther, Rojo, Federico, Gómez, Javier, Enguita, Ana Belén, Abdulkader, Ihab, González, Ana, Lozano, Dolores, Mancheño, Nuria, Salas, Clara, Salido, Marta, Salido-Ruiz, Eduardo, and de Álava, Enrique

Abstract

The effectiveness of targeted therapies with tyrosine kinase inhibitors in non-small-cell lung cancer (NSCLC) depends on the accurate determination of the genomic status of the tumour. For this reason, molecular analyses to detect genetic rearrangements in some genes (ie, ALK, ROS1, RET and NTRK) have become standard in patients with advanced disease. Since immunohistochemistry is easier to implement and interpret, it is normally used as the screening procedure, while fluorescence in situ hybridisation (FISH) is used to confirm the rearrangement and decide on ambiguous immunostainings. Although FISH is considered the most sensitive method for the detection of ALKand ROS1rearrangements, the interpretation of results requires detailed guidelines. In this review, we discuss the various technologies available to evaluate ALKand ROS1genomic rearrangements using these techniques. Other techniques such as real-time PCR and next-generation sequencing have been developed recently to evaluate ALKand ROS1gene rearrangements, but some limitations prevent their full implementation in the clinical setting. Similarly, liquid biopsies have the potential to change the treatment of patients with advanced lung cancer, but further research is required before this technology can be applied in routine clinical practice. We discuss the technical requirements of laboratories in the light of quality assurance programmes. Finally, we review the recent updates made to the guidelines for the determination of molecular biomarkers in patients with NSCLC.

Published
2022
Full Text
View/download PDF

16. RETFusion Testing in Patients With NSCLC: The RETING Study

Author

Conde, Esther, Hernandez, Susana, Rodriguez Carrillo, Jose Luis, Martinez, Rebeca, Alonso, Marta, Curto, Daniel, Jimenez, Beatriz, Caminoa, Alejandra, Benito, Amparo, Garrido, Pilar, Clave, Sergi, Arriola, Edurne, Esteban-Rodriguez, Isabel, De Castro, Javier, Sansano, Irene, Felip, Enriqueta, Rojo, Federico, Dómine, Manuel, Abdulkader, Ihab, Garcia-Gonzalez, Jorge, Teixido, Cristina, Reguart, Noemi, Compañ, Desamparados, Insa, Amelia, Mancheño, Nuria, Palanca, Sarai, Juan-Vidal, Oscar, Baixeras, Nuria, Nadal, Ernest, Cebollero, Maria, Calles, Antonio, Martin, Paloma, Salas, Clara, Provencio, Mariano, Aranda, Ignacio, Massuti, Bartomeu, Lopez-Vilaro, Laura, Majem, Margarita, Paz-Ares, Luis, and Lopez-Rios, Fernando

Abstract

RETinhibitors with impressive overall response rates are now available for patients with NSCLC, yet the identification of RETfusions remains a difficult challenge. Most guidelines encourage the upfront use of next-generation sequencing (NGS), or alternatively, fluorescence in situ hybridization (FISH) or reverse transcriptase-polymerase chain reaction (RT-PCR) when NGS is not possible or available. Taken together, the suboptimal performance of single-analyte assays to detect RETfusions, although consistent with the notion of encouraging universal NGS, is currently widening some of the clinical practice gaps in the implementation of predictive biomarkers in patients with advanced NSCLC.

Published
2024
Full Text
View/download PDF

19. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

Author

Conde, Esther, Hernandez, Susana, Martinez, Rebeca, Angulo, Barbara, De Castro, Javier, Collazo-Lorduy, Ana, Jimenez, Beatriz, Muriel, Alfonso, Mate, Jose Luis, Moran, Teresa, Aranda, Ignacio, Massuti, Bartomeu, Rojo, Federico, Domine, Manuel, Sansano, Irene, Garcia, Felip, Felip, Enriqueta, Mancheño, Nuria, Juan, Oscar, Sanz, Julian, Gonzalez-Larriba, Jose Luis, Atienza-Cuevas, Lidia, Arriola-Arellano, Esperanza, Abdulkader, Ihab, Garcia-Gonzalez, Jorge, Camacho, Carmen, Rodriguez-Abreu, Delvys, Teixido, Cristina, Reguart, Noemi, Gonzalez-Piñeiro, Ana, Lazaro-Quintela, Martin, Lozano, Maria Dolores, Gurpide, Alfonso, Gomez-Roman, Javier, Lopez-Brea, Marta, Pijuan, Lara, Salido, Marta, Arriola, Edurne, Company, Amparo, Insa, Amelia, Esteban-Rodriguez, Isabel, Saiz, Monica, Azkona, Eider, Alvarez, Ramiro, Artal, Angel, Plaza, Maria Luz, Aguiar, David, Enguita, Ana Belen, Benito, Amparo, Paz-Ares, Luis, Garrido, Pilar, and Lopez-Rios, Fernando

Abstract

The ROS1gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology testing guidelines support the use of ROS1 immunohistochemistry (IHC) as a screening test, followed by confirmation with fluorescence in situ hybridization (FISH) or a molecular test in all positive results. We have evaluated a novel anti-ROS1 IHC antibody (SP384) in a large multicenter series to obtain real-world data.

Published
2019
Full Text
View/download PDF

21. Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital.

Author

Simarro, Javier, Murria, Rosa, Pérez-Simó, Gema, Llop, Marta, Mancheño, Nuria, Ramos, David, de Juan, Inmaculada, Barragán, Eva, Laiz, Begoña, Cases, Enrique, Ansótegui, Emilio, Gómez-Codina, José, Aparicio, Jorge, Salvador, Carmen, Juan, Óscar, and Palanca, Sarai

Subjects
COLON tumors, LUNG cancer, GENETIC mutation, ONCOGENES, MOLECULAR pathology, RECTUM tumors, TUMORS, GENETIC markers, COST analysis, TURNAROUND time, INDIVIDUALIZED medicine, SEQUENCE analysis
Abstract

The establishment of precision medicine in cancer patients requires the study of several biomarkers. Single-gene testing approaches are limited by sample availability and turnaround time. Next generation sequencing (NGS) provides an alternative for detecting genetic alterations in several genes with low sample requirements. Here we show the implementation to routine diagnostics of a NGS assay under International Organization for Standardization (UNE-EN ISO 15189:2013) accreditation. For this purpose, 106 non-small cell lung cancer (NSCLC) and 102 metastatic colorectal cancer (mCRC) specimens were selected for NGS analysis with Oncomine Solid Tumor (ThermoFisher). In NSCLC the most prevalently mutated gene was TP53 (49%), followed by KRAS (31%) and EGFR (13%); in mCRC, TP53 (50%), KRAS (48%) and PIK3CA (16%) were the most frequently mutated genes. Moreover, NGS identified actionable genetic alterations in 58% of NSCLC patients, and 49% of mCRC patients did not harbor primary resistance mechanisms to anti-EGFR treatment. Validation with conventional approaches showed an overall agreement >90%. Turnaround time and cost analysis revealed that NGS implementation is feasible in the public healthcare context. Therefore, NGS is a multiplexed molecular diagnostic tool able to overcome the limitations of current molecular diagnosis in advanced cancer, allowing an improved and economically sustainable molecular profiling. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results